The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCL
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, presents findings from the Phase III POLARIX trial (NCT03274492), which assessed polatuzumab vedotin, an antibody-drug conjugate, with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with diffuse large B-cell lymphoma (DLBCL). Patients were randomized to receive either polatuzumab vedotin with R-CHP or the current standard of care, R-CHOP (R-CHP with vincristine), with the primary endpoint being progression-free survival. Polatuzumab vedotin significantly improved PFS compared to R-CHOP, and reduced the rate of relapse. A toxicity profile similar to that of the standard of care was additionally reported. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
